Barbara Ann Karmanos Cancer Institute | Detroit, MI
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.
Full description
This first-in-human, phase 1 study will consist of 2 parts. In Part A (Dose Escalation), the primary objectives will be to investigate the safety and tolerability of DS-9606a in advanced solid tumors and to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE). In Part B (Dose Expansion), the safety and tolerability of DS-9606a will be further explored and the overall response rate will be assessed.
The secondary objectives of the study will assess pharmacokinetic properties of DS-9606a and investigate the duration of response and progression-free survival of DS-9606a, and assess the immunogenicity of DS-9606a.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Dose Escalation Participants Only:
Dose Expansion Participants Only:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
85 participants in 2 patient groups
Loading...
Central trial contact
Contact for Clinical Trial Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal